Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-1953 in acne vulgaris
NCT03900676Phase 2Unknown
- Sponsor
- Vyome Therapeutics Inc.
- Start
- Apr 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VB-1953 in acne vulgaris (4 arms), sponsored by Vyome Therapeutics Inc. Primary endpoint: Absolute change from baseline in inflammatory lesion counts at 12 weeks. Status: unknown.
02
Drugs
VB-1953
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03900676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900676.